Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species

Y. Niitsu(Daiichi-Sankyo (Japan)), Fumitoshi Asai(Azabu University), Taketoshi Ogawa(Biomedical Research Laboratories (United States)), Masami Hashimoto(Daiichi-Sankyo (Japan)), Joseph A. Jakubowski(Indiana Biosciences Research Institute), Ken‐ichi Otsuguro(Hokkaido University), Takashi Isobe(Hamamatsu Photonics (United Kingdom)), Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom))
European Journal of Pharmacology
November 10, 2007
10.1016/j.ejphar.2007.10.005
Cited by 47

Related Papers

Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
|American Heart Journal|2006|571
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
|European Heart Journal|2006|537